Review Article Open Access
Volume 2 | Issue 3 | DOI: https://doi.org/10.46439/cancerbiology.2.029
Immuno-oncologic care during COVID-19: Challenges and opportunities for improving clinical care and investigation
Kristen Spencer1,*, Eric A. Singer2, Eugenia Girda3
- 1Division of Medical Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, Unites States
- 2Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, Unites States
- 3Division of Gynecologic Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, Unites States
Corresponding Author
Kristen Spencer, spencekr@cinj.rutgers.edu
Received Date: March 15, 2021
Accepted Date: August 16, 2021
Spencer K, Singer EA, Girda E. Immuno-oncologic care during COVID-19: Challenges and opportunities for improving clinical care and investigation. J Cancer Biol 2021; 2(3): 75-82.
Copyright: © 2021 Spencer K, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, n and reproduction in any medium, provided the original author and source are credited.
Abstract
Cancer care has been greatly impacted during the COVID-19 pandemic. The number of cases and deaths caused by the COVID-19 pandemic continues to escalate throughout the United States and the world. Worldwide, over 150 million people have been diagnosed with the coronavirus and more than 3 million have died. Now that we have gained additional experience with COVID-19, we are starting to learn its full impact on oncology care and its effects on the practice of medicine and clinical research.
Keywords
COVID-19, Cancer, Pandemic, Immunotherapy
Recommended Articles
Planned procedures and covid-19 pandemic: Does recovery plan, a matter of urgency?
The COVID-19 pandemic brought many challenges to each sector of life. The most affected are the health in general and elective services in specific. The postponement of planned surgical procedures is one of the elective services that not only increased the waiting time in the short-term but will strain the healthcare services in the long-run
Harnessing innovation for the future of breast cancer management
Breast cancer is the most commonly diagnosed cancer and the second leading cause of cancerrelated mortality in women worldwide. Incidence rates continue to rise globally. Breast cancer encompasses a heterogeneous group of tumors with varying molecular features, clinical behaviors, and responses to therapy. While survival rates have improved, challenges persist such as invasive cancers, recurrent metastatic disease, and mortality among subgroups.
A scoping review of outcome measures in ovarian cancer clinical trials
The incorporation of patient-reported outcomes (PROs) is essential for assessing whether a cancer treatment enhances overall patient well-being, beyond merely extending survival. This scoping review aimed to identify and analyze the use of PROs in ovarian cancer clinical trials.
Significance of BRCA genetic testing for preoperative breast cancer patients
Examining BRCA mutations in preoperative breast cancer patients is very important when selecting a surgical procedure. Although there are advantages and disadvantages associated with knowing about the presence of genetic mutations, including for the patient’s family, there are many benefits for the patient. BRCA genetic testing should be recommended for patients who are strongly suspected of being positive for a BRCA mutation.
Molecular signatures of aggressive pediatric liver cancer
Liver masses account for 5 to 6% of pediatric cancer, which includes hepatoblastoma (HBL) along with rare cases of hepatocellular carcinoma (HCC). The most dangerous form of pediatric liver cancer is aggressive HBL, which can be characterized by chemo-resistance and multiple nodules or metastases at diagnosis, all correlating with worse clinical prognosis. Despite intensive studies and a significant improvement in overall outcomes, very little is known about the key molecular pathways which determine the aggressiveness of pediatric liver cancer.